A Phase I/II Study of TTI-622 in Combination with Pegylated Liposomal Doxorubicin in Patients with Platinum-Resistant Ovarian Cancer
A Phase I/II Study of TTI-622 in Combination with Pegylated Liposomal Doxorubicin in Patients with Platinum-Resistant Ovarian Cancer
-
Clinical Trial Information
Trial Contact: Donaldson, Karin M; Grofsik, Kiera; Frankos, Marie; Djuro, Victor; Walton, Sherri
Trial Phone: 321.841.9821 ; 321.841.6626 ; 321.841.7303 ; 321.841.7477 ; 321.841.1907
-
IRB No: 22.031.02
Protocol Abbrev: TTI-622-02
Principal Investigator: Shelly Marie Seward, MD
Phase: Drug: Phase I
Age Group: Adult
Secondary Protocol No: C4971002, Trillium ZZA82397
Treatment: TTI-622 (SIRPĪ±-IgG4 Fc)
Therapies Involved: Chemotherapy
ClinicalTrials.gov ID: NCT05261490
-
Objective
Primary Objectives:
1. Evaluate the safety of escalating dose levels of TTI-622 when administered in combination with 40 mg/m2 PLD in 28-day cycles and establish the MTD and/or RP2D combination
regimen (Phase I portion of study)
2. Gain a preliminary assessment of clinical activy of TTI-622 in combination with 40 mg/m2 PLD (Phase II portion of study)
